X0202 SCHEDULE 13G/A 0001948604 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 03/31/2026 0001885522 Neumora Therapeutics, Inc. 640979100 260 Arsenal Place Suite 1 Watertown MA 02472 Rule 13d-1(c) K2 HealthVentures Equity Trust LLC DE 0 5790453 0 5790453 5790453 N 3.1 OO Parag Shah X1 0 5790453 0 5790453 5790453 N 3.1 IN HC Anup Arora X1 0 5790453 0 5790453 5790453 N 3.1 IN HC Neumora Therapeutics, Inc. 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472 This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"): i. K2 HealthVentures Equity Trust LLC ("K2HV Equity"); ii. Parag Shah ("Mr. Shah"); and iii. Anup Arora ("Mr. Arora"). This Statement on Schedule 13G relates to an aggregate 5,790,453 shares of Common Stock K2HV Equity has the right to acquire within 60 days upon conversion of the remaining balance of the Issuer's outstanding debt obligations to K2HV Equity under the Loan and Security Agreement, dated as of May 9, 2025, between the Issuer and K2HV Equity, as amended by the First Amendment to Loan and Security Agreement, dated as of November 4, 2025, including (i) 4,558,926 shares of Common Stock that are issuable at a conversion price of the lesser of $0.8774 per share and the lowest effective price per share of the Issuer's next equity financing (the "Original Conversion Shares"), and (ii) 1,231,527 shares of Common Stock that are issuable at a conversion price of $2.03 per share, which is, as of the date of this Statement on Schedule 13G, the lesser of (a) $2.3906 per share and (b) the lowest effective price per share in the Issuer's equity financing in Q1 2026 (the "Amendment Conversion Shares" and, together with the Original Conversion Shares, the "Conversion Shares"). For purposes of this Schedule 13G, we have assumed a conversion price of $0.8774 per share for the Original Conversion Shares and $2.03 for the Amendment Conversion Shares. K2HV Equity is an investment vehicle for holding equity securities and may be deemed to directly beneficially own the shares of Common Stock that it has the right to acquire upon conversion of the Conversion Shares, as reported herein. Mr. Shah and Mr. Arora serve as the managing members of K2HV Equity and, in such capacities, may be deemed to indirectly beneficially own the shares of Common Stock that K2HV Equity directly beneficially owns. The business address of each of the Reporting Persons is: 855 Boylston Street, 10th Floor, Boston, MA 02116. K2HV Equity is a Delaware limited liability company. Each of Mr. Shah and Mr. Arora is a citizen of the United States of America. Y As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of 5,790,453 shares of Common Stock. This amount consists of an aggregate 5,790,453 shares of Common Stock K2HV Equity has the right to acquire upon conversion of the Conversion Shares. As of March 31, 2026, each of the Reporting Persons may be deemed the beneficial owner of approximately 3.1% of the shares of Common Stock outstanding. The percentage set forth herein is calculated based on the sum of (i) 182,157,466 shares of Common Stock outstanding as of March 31, 2026, as reported in the Issuer's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission on May 7, 2026, and (ii) an aggregate 5,790,453 shares of Common Stock that are issuable to K2HV Equity within 60 days upon conversion of the Conversion Shares, which Conversion Shares have been added to the total shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended. 0 5,790,453 0 5,790,453 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. K2 HealthVentures Equity Trust LLC /s/ Anup Arora 05/15/2026 Parag Shah /s/ Parag Shah 05/15/2026 Anup Arora /s/ Anup Arora 05/15/2026